ArticleJournal of inflammation research2025
Network Pharmacology Combined with Animal Experiments Elucidates the Mechanism of Effect of Xin'an Formula in Treating Allergic Rhinitis.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Exploring the mechanism of the effect of Xin'an BiYan Formula (XBY) in treating allergic rhinitis (AR) using network pharmacology combined with animal experiments. Methods: Key targets for AR treatment were identified through multi-database and PPI network screening. Potential signaling pathways were predicted by conducting Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses. The predicted targets and pathways in animal experiments to learn XBY's effects on inflammation and apoptosis in nasal mucosal tissue cells during AR development. Results: Screening identified 18 principal targets of XBY in AR: TNF, AKT1, HIF1A, MMP9, BCL2, EGFR, IL-2, PTGS2, VCAM-1, PTGS1, ACE, PPARG, ICAM-1, SIRT1, ITGB1, JAK2, RELA, and KIT. The key pharmacological constituents included Genkwanin, Calycosin, Kaempferol, and Luteolin. GO and KEGG enrichment analyses revealed significant enrichment in the PI3K/AKT, Apoptosis, and NF-kappa B signaling pathways. After XBY treatment, infiltration of eosinophils (EOS) and mast cells (MC) in the nasal mucosa of AR model mice was reduced. Concurrently, serum levels of IL-6, TNF-α, COX-2, Total-IgE, OVA-IgE, ICAM-1, and VCAM-1 were decreased. Mucosal levels of p-PI3K/PI3K, p-AKT/AKT, p-n-p65/c-p65, p-IKKβ/ IKKβ, and Bcl-2 proteins were decreased, while Bax, Cleaved-Caspase3, and Caspase-3 protein expression were increased. Cellular levels of reactive oxygen species(ROS) and apoptosis levels were reduced. Conclusion: The experimental results indicate that the therapeutic effect of XBY on AR is likely mediated through modulation of the ROS/PI3K/AKT/NFκB signaling pathway. By reducing inflammatory cell infiltration, downregulating the expression of inflammatory and adhesion factors, and modulating apoptosis proteins to accelerate inflammatory cell apoptosis, dual mechanisms effectively inhibit the progression of inflammation. This study holds potential translational prospects and may provide new insights for the treatment of AR with TCM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.